Fractyl Health, Inc. GUTS 深 沪
已收盘 11-28 16:00:00 美东时间
1.57
+0.090
+6.08%
华盛通- 最 高1.57
- 今 开1.49
- 成交量 189.12万股
- 最 低 1.48
- 昨 收 1.48
- 总市值 2.15亿
- 52周最高 3.03
- 市盈率 静 --
- 换手率 1.38%
- 52周最低 0.825
- 委 比 -19.79%
- 总股本 1.37亿
- 历史最高 14.50
- 量 比 0.90
- 振 幅 6.08%
- 历史最低 0.825
- 每 手 1
- 风险率 0.40%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 最高130美元！11家大行集体上调沃尔玛目标价；戴康工业、Gap、罗斯百货等均或多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Fractyl Health"买入"评级，目标价从6美元升至8美元；HC Wainwright & Co.：维持MediWound"买入"评级，目标价从31美元升至36美元
11-24 11:23
Canaccord Genuity Maintains Buy on Fractyl Health, Raises Price Target to $8
Canaccord Genuity analyst Whitney Ijem maintains Fractyl Health (NASDAQ:GUTS) with a Buy and raises the price target from $6 to $8.
11-22 02:30
Earnings Scheduled For November 12, 2025
Companies Reporting Before The Bell • Hudbay Minerals (NYSE:HBM) is projected t...
11-12 19:11
Preview: Fractyl Health's Earnings
Fractyl Health (NASDAQ:GUTS) will release its quarterly earnings report on Wedn...
11-12 01:12
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, Oct. 21, 2025 /PRNewswire/ -- Equity InsiderNews Commentary – Conventional small molecule approaches hav...
10-21 21:20
Fractyl Health Unveils Preclinical Results for RJVA-002, Showing 30% Weight Loss in Obesity Model
Fractyl Health, Inc. (NASDAQ:GUTS) (the Company), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes of obesity and type 2 diabetes (T2D), today announced potent new
10-07 19:12
Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity
Fractyl Health announced potent preclinical data for RJVA-002, a gene therapy targeting obesity, showing ~30% weight loss in 5 weeks in a translational obesity model. This dual GIP/GLP-1 therapy demonstrates significant and durable efficacy, potentially rivaling chronic drug treatments. The company aims to expand its Rejuva platform beyond T2D to obesity, highlighting a novel approach for durable weight loss through a single administration.
10-07 11:00
美股大行评级 | 潜在涨幅485.44%！Allarity Therapeutics获机构升目标价至9.25美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从9美元升至9.25美元；JMP证券：维持Crinetics Pharmaceuticals"跑赢大市"评级，目标价从86美元升至143美元
09-29 09:15
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers bioAffinity Technologies (NASDAQ: BIAF) stock increased by 71.8% to $5.86 during Friday's pre-market session. The company's market cap stands at $4.5 million.
09-26 20:10
Fractyl Health Reveals Promising REMAIN-1 Study Results
The latest update is out from Fractyl Health, Inc. ( ($GUTS) ). On September 26...
09-26 19:28
